Latest News

Martin Schoen, MD, PhD, discusses factors guiding ARPI selection in prostate cancer and how real-world evidence can help inform treatment decisions.

Closing racial disparities in prostate cancer requires meeting men in barbershops, churches, and community screenings—not just clinics, according to Justin Cohen, MD.

A recap of the FDA submissions and regulatory decisions in urology from August 2026.

Prof Declan Murphy discusses PROTEUS pathologic responses with apalutamide plus ADT and their implications for future treatment strategies.

In this Q&A, Zachary Feuer, MD, discusses the implementation of a telehealth-based rapid access program for evaluating men with an elevated PSA.

Timothy D. McClure, MD, discusses 2-year PRESERVE trial safety data and 12-month AUA findings linking prostate size to IPSS improvement after focal IRE.

Mary Dunn, MSN, RN, NP-C, OCN, discusses how APPs support genetic testing through patient counseling, test ordering, result communication, and referrals to genetics specialists.

The FDA has granted clearance to a phase 1 trial of ADI-212, a PSMA-targeted, gene-edited, armored cell therapy candidate under development for mCRPC.

University of Florida urology chiefs Miranda Eubank, MD; Trisha Nguyen, MD; and Jordan Matthews-Smith, MD, reflect on residency milestones, mentorship, community, and lessons learned along the way.

Emanuele Crupi, MD, discusses prospective data supporting GemFLP as a benchmark for treatment of advanced urachal and non-urachal urinary tract adenocarcinomas.

A TRUMPET registry analysis found that initial disease presentation and family history were associated with survival outcomes in metastatic castration-resistant prostate cancer.

Nicole L. Miller, MD, FACS, discusses how to distinguish bladder dysfunction from persistent obstruction when evaluating LUTS after BPH treatment.

Andrew J. Hung, MD, discusses an AI system that analyzes surgical gestures and identifies technique patterns linked to erectile function recovery after prostatectomy.